By Colin Kellaher
Synlogic on Wednesday said it plans to study its SYNB1891 Synthetic Biotic medicine in combination with Roche Holding cancer immunotherapy Tecentriq in patients with advanced solid tumors under a collaboration with the Swiss drugmaker.
Synlogic, a Cambridge, Mass., clinical-stage biopharmaceutical company, said it expects to file an investigational new drug application with the U.S. Federal Drug Administration to begin an open-label Phase 1 clinical trial evaluating SYNB1891 as a monotherapy and a combination treatment with Tecentriq.
Synlogic said it will sponsor the study, while Roche will provide the clinical supply of Tecentriq.
Write to Colin Kellaher at firstname.lastname@example.org